{Reference Type}: Journal Article
{Title}: Clinical outcomes of image-guided therapies in patients with adrenocortical carcinoma: a tertiary referral center retrospective study.
{Author}: Chahla B;Pal K;Balderrama-Brondani V;Yaylaci F;Campbell MT;Sheth RA;Habra MA;
{Journal}: Oncologist
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jun 13
{Factor}: 5.837
{DOI}: 10.1093/oncolo/oyae130
{Abstract}: <B>BACKGROUND: </B>Image-guided therapies (IGTs) are commonly used in oncology, but their role in adrenocortical carcinoma (ACC) is not well defined.<BR><B>METHODS: </B>A retrospective review of patients with ACC treated with IGTs. We assessed response to therapy using RECIST v1.1, time to next line of systemic therapy, disease control rate (DCR), local tumor progression-free survival (LTPFS), and complications of IGTs (based on the Common Terminology Criteria for Adverse Events [CTCAE] version 5.0).<BR><B>RESULTS: </B>Our cohort included 26 patients (median age 56 years [range 38-76]; n = 18 female) who had 51 IGT sessions to treat 86 lesions. IGTs modalities included cryoablation (n = 49), microwave ablation (n = 21), combined microwave and bland trans-arterial embolization (n = 8), bland trans-arterial embolization alone (n = 3), radio-embolization (n = 3), and radiofrequency ablation (n = 2). DCR was 81.4% (70 out of 86), of which 66.3% of tumors showed complete response, 18.6% showed progressive disease, 8.1% showed partial response, and 7.0% showed stable disease. LTPFS rates were 73% and 63% at 1 and 2 years, respectively. Fourteen lesions underwent re-ablation for incomplete response on initial treatment. Sixteen patients (61.5%) received new systemic therapy following IGTs, with a median time to systemic therapy of 12.5 months (95% CI: 8.6 months upper limit not reached). There was 1 reported CTCAE grade 3 adverse event (biloma) following IGT.<BR><B>CONCLUSIONS: </B>IGT use in properly selected patients with ACC is safe and associated with prolonged disease control and delay in the need for systemic therapy.